Financial PerformanceLigand reported financial results with revenues of $45.3 million, an increase of 46% year-over-year, and higher adjusted earnings of $1.33 per share, boosted by higher sales of Ligand's Captisol excipient and increased royalty revenues from licensed products.
Growth ProspectsLigand investors can expect several catalysts including continued growth from new products and potential clinical progress from partners.
Strategic DevelopmentsHighlights for Ligand included recent launches of new drugs and clinical progress in new therapeutic areas, along with the completion of the Pelthos Therapeutics spin-off into a new public company.